GlassScriptPhysician profile
Richard S Mandel
NPI 1346271244
$9,729.96
in general payments reported to CMS, 2019-2025
53 companies · $1,683 in 2025
The $1,683 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $839 · 2020: $1,054 · 2021: $1,444 · 2022: $1,288 · 2023: $1,667 · 2024: $1,755 · 2025: $1,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,098 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,098.28 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,697.73 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,070.45 | 2019-2025 | |
| Pfizer INC. | $866.02 | 2019-2025 | |
| Novo Nordisk INC | $816.88 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $559.24 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Abbott Laboratories | $492.17 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Amarin Pharma, INC. | $443.93 | 2019-2022 | |
| Glaxosmithkline, LLC. | $386.07 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $305.82 | 2020-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.48 | 2019-2025 | Jardiance, Ofev |
| Exact Sciences Corporation | $290.93 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $210.82 | 2019-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $199.63 | 2019-2024 | Lagevrio |
| Hologic Sales and Service, LLC | $155.64 | 2025 | Aptima |
| Astellas Pharma US INC | $136.91 | 2019-2025 | Veozah, Myrbetriq |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Mandel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.